<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04531631</url>
  </required_header>
  <id_info>
    <org_study_id>CRE-2020.196</org_study_id>
    <nct_id>NCT04531631</nct_id>
  </id_info>
  <brief_title>Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in Individuals With Recent-onset Type 2 Diabetes and Monogenic Diabetes</brief_title>
  <official_title>Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in Individuals With Recent-onset Type 2 Diabetes and Monogenic Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes is a disorder of energy energy metabolism. Glucose is the main energy substrate for&#xD;
      generation of ATP to maintain cellular metabolism, structure and function. Glucokinase (GK)&#xD;
      serves as a glucose sensor for the initiation of the energy generation.for energy metabolism.&#xD;
      Dorzagliatin is a novel, first-in-class, dual-acting allosteric GK activator (GKA). It&#xD;
      increases the affinity of GK for glucose by directly binding a pocket distal to its active&#xD;
      site, thus lowering the set point for glucose-stimulated insulin secretion in the beta-cell.&#xD;
&#xD;
      Dorzagliatin is a new drug which acts as GK sensor activator (GKA). It can restore the&#xD;
      sensitivity of the pancreas cells to glucose and improve glucose control. The drug has been&#xD;
      trialled in healthy volunteers and in individuals with type 2 diabetes.&#xD;
&#xD;
      The aim of this study is to understand the way in which dorzagliatin works to improve blood&#xD;
      sugar control in people with diabetes. The study will look at how dorzagliatin affects&#xD;
      insulin secretion and the sensitivity of the pancreas to changes in blood sugar levels. We&#xD;
      will examine whether dorzagliatin can restore the function of this GK sensor in patients with&#xD;
      known mutations. In a cross-over study, we will evaluate the effects of dorzagliatin, a&#xD;
      specific GKA versus placebo in terms of insulin secretion and beta-cell glucose sensitivity&#xD;
      in patients with newly-diagnosed T2D and patients who are known heterozygous carriers of GK&#xD;
      mutations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>first phase insulin response to glucose</measure>
    <time_frame>10 mins</time_frame>
    <description>measure insulin between 0 to 10 minutes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>First phase C-peptide responses to glucose</measure>
    <time_frame>10 mins</time_frame>
    <description>measure C peptide between 0 to 10 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) 1st phase insulin between 0 to 10 minutes</measure>
    <time_frame>10 mins</time_frame>
    <description>measure insulin between 0 to 10 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum (Tmax) of acute phase insulin response between 0 to 10 minutes</measure>
    <time_frame>10 mins</time_frame>
    <description>measure insulin between 0 to 10 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Second phase insulin response</measure>
    <time_frame>40 mins</time_frame>
    <description>measure insulin at last 40 mins of hyperglycemic clamp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beta cell glucose sensitivity</measure>
    <time_frame>40 mins</time_frame>
    <description>insulin secretion in last 40 minutes of hyperglycemic clamp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity index</measure>
    <time_frame>40 mins</time_frame>
    <description>glucose infusion rate in last 40 minutes of hyperglycemic clamp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under curve of glucagon levels</measure>
    <time_frame>120 mins</time_frame>
    <description>measure glucagon from 0-120 mins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under curve of GLP-1 levels</measure>
    <time_frame>120 mins</time_frame>
    <description>measure GLP-1 from 0-120 mins</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>receive a single oral dose of dorzagliatin 75mg tablet on visit 2 and receive one placebo tablet on visit 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>receive a single oral dose of one placebo tablet on visit 2 and receive dorzagliatin 75mg tablet on visit 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dorzagliatin</intervention_name>
    <description>tablet</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Individuals aged â‰¥ 18 years but &lt; 65years&#xD;
&#xD;
          2. Male or female&#xD;
&#xD;
          3. Body mass index of over 18 kg/m2 and &lt; 30 kg/m2 Additional Inclusion criteria for&#xD;
             recent-onset T2D group&#xD;
&#xD;
               -  Diagnosis of T2D for at least 3 months and less than 2 years&#xD;
&#xD;
               -  On diet control only&#xD;
&#xD;
               -  HbA1c&gt;6.5 % and &lt;8% Additional Inclusion criteria for GK MODY-2 group&#xD;
&#xD;
               -  Abnormal fasting plasma glucose &gt;5.6 mmol/l and known heterozygous carrier of&#xD;
                  pathogenic GK mutation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who do not agree to participate in this study.&#xD;
&#xD;
          2. Country of birth is unknown&#xD;
&#xD;
          3. Body weight less than 45kg&#xD;
&#xD;
          4. Acute phase of cerebrovascular and cardiovascular diseases (within 6 months of&#xD;
             recruitment).&#xD;
&#xD;
          5. Subjects with severe renal dysfunction as defined by eGFR &lt;30 ml/min/1.73m2 or&#xD;
             patients receiving renal dialysis (such as haemodialysis or continuous ambulatory&#xD;
             peritoneal dialysis).&#xD;
&#xD;
          6. Severe hepatic dysfunction as defined by AST and/or ALT &gt; 3 times upper limit of&#xD;
             normal&#xD;
&#xD;
          7. Severe cardiovascular disease, history of stroke, heart failure (NYHA III or IV) or&#xD;
             history of myocardial infarction within last 12 months&#xD;
&#xD;
          8. History of drug abuse or excessive alcohol intake based on investigator judgment&#xD;
&#xD;
          9. Severe hypoglycaemia resulting in seizure/unconsciousness/coma/hospitalization in the&#xD;
             last 3 months before screening&#xD;
&#xD;
         10. Diagnosis with Type 1 Diabetes Mellitus (T1DM) or any previous episodes of diabetic&#xD;
             ketoacidosis.&#xD;
&#xD;
         11. Dehydration, diarrhoea or vomiting at the time of recruitment&#xD;
&#xD;
         12. Subjects with severe infection, in perioperative period or with serious injury at the&#xD;
             time of recruitment&#xD;
&#xD;
         13. Subjects with anaemia (Haemoglobin &lt;9.0mg/dL)&#xD;
&#xD;
         14. Pregnant or lactating or intending to become pregnant within 30 days after last dose&#xD;
             of study drug.&#xD;
&#xD;
         15. Participation in a clinical trial within 30 days before enrolment&#xD;
&#xD;
         16. Donation or loss of blood (excluding the volume of blood that will be drawn during&#xD;
             screening procedures) as follows: &gt;=300 mL of blood within 30 days prior to study drug&#xD;
             administration.&#xD;
&#xD;
         17. Subjects judged unsuitable for the study based on investigator judgment&#xD;
&#xD;
         18. Use of metformin, sulfonylureas, dipeptidyl peptidase-4 inhibitors, glucagon-like&#xD;
             peptide 1 [GLP-1] agonists, sodium glucose transporter 2 inhibitors, insulin,&#xD;
             thiazolidinediones, acarbose in the 3 months prior to study enrolment will not be&#xD;
             permitted.&#xD;
&#xD;
         19. Use of strong or moderate CYP3A4 inhibitors or inducers and cannot be discontinued&#xD;
&#xD;
         20. Unwilling or unable to follow protocol requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Chinese University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juliana Chan</last_name>
      <phone>35053138</phone>
      <email>jchan@cuhk.edu.hk</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 26, 2020</study_first_submitted>
  <study_first_submitted_qc>August 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Juliana Chan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

